The Latest Analyst Ratings for Humana
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 8 Wall Street analysts have published their opinions on Humana (NYSE:HUM) stock, with 7 out of 8 showing a positive stance (2 bullish, 5 somewhat bullish) and 1 indifferent. The average 12-month price target for Humana is $583.88, with a high of $599.00 and a low of $550.00, representing a slight decrease of 0.28% from the previous target of $585.50. Analysts typically review stocks quarterly or after major company updates, using financial predictions and company performance to guide their ratings.
December 12, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Humana has received mostly positive ratings from analysts, with an average price target slightly lower than the previous one. This indicates a generally favorable outlook but with a cautious adjustment in valuation.
The majority of analysts have a positive outlook on Humana, which could be a good sign for investors. However, the slight decrease in the average price target suggests a conservative approach to the stock's future valuation. Given that the ratings are mostly positive, the short-term impact on the stock is likely to be neutral as the market has likely already priced in the optimistic views, and the minor decrease in the target price does not suggest a significant change in market sentiment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100